Generic Oretic Availability
Oretic is a brand name of hydrochlorothiazide, approved by the FDA in the following formulation(s):
ORETIC (hydrochlorothiazide - tablet; oral)
-
Manufacturer: ABBVIE
Approved Prior to Jan 1, 1982
Strength(s): 50MG [AB]
Has a generic version of Oretic been approved?
Yes. The following products are equivalent to Oretic:
hydrochlorothiazide tablet; oral
-
Manufacturer: ACCORD HLTHCARE
Approval date: September 24, 2012
Strength(s): 50MG [AB] -
Manufacturer: APOTEX
Approval date: October 3, 2007
Strength(s): 50MG [AB] -
Manufacturer: AUROBINDO PHARMA
Approval date: July 20, 2007
Strength(s): 50MG [AB] -
Manufacturer: CARACO
Approval date: March 27, 2007
Strength(s): 50MG [AB] -
Manufacturer: DAVA PHARMS INC
Approved Prior to Jan 1, 1982
Strength(s): 50MG [AB] -
Manufacturer: EXCELLIUM
Approval date: March 16, 2007
Strength(s): 50MG [AB] -
Manufacturer: HERITAGE PHARMS INC
Approved Prior to Jan 1, 1982
Strength(s): 50MG [AB] -
Manufacturer: IPCA LABS LTD
Approval date: July 20, 2007
Strength(s): 50MG [AB] -
Manufacturer: JUBILANT CADISTA
Approval date: September 4, 2007
Strength(s): 50MG [AB] -
Manufacturer: LANNETT
Approved Prior to Jan 1, 1982
Strength(s): 50MG [AB] -
Manufacturer: MYLAN PHARMS INC
Approval date: January 23, 2007
Strength(s): 50MG [AB] -
Manufacturer: UNICHEM
Approval date: August 15, 2008
Strength(s): 50MG [AB] -
Manufacturer: VINTAGE PHARMS
Approval date: March 29, 2002
Strength(s): 50MG [AB] -
Manufacturer: WEST WARD
Approved Prior to Jan 1, 1982
Strength(s): 50MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oretic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
There are no current U.S. patents associated with Oretic.
See also...
- HCTZ Consumer Information (Drugs.com)
- Hydrochlorothiazide Consumer Information (Drugs.com)
- Hydrochlorothiazide Consumer Information (Wolters Kluwer)
- Hydrochlorothiazide capsules Consumer Information (Wolters Kluwer)
- Hydrochlorothiazide solution Consumer Information (Wolters Kluwer)
- Hydrochlorothiazide Consumer Information (Cerner Multum)
- Hydrocot Advanced Consumer Information (Micromedex)
- Zide Advanced Consumer Information (Micromedex)
- Hydrochlorothiazide Advanced Consumer Information (Micromedex)
- Hydrochlorothiazide AHFS DI Monographs (ASHP)
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |


